


Three Topics

- **Project Selection and Prioritization**
- **Private-sector partnerships driving translation**
- **Public – Private Partnership Model**


Confronting a Broad Spectrum of Diseases With Diverse Outcomes

Comparison of Diseases by Survival Rate, Age of Onset & Incidence




SEER database, scientific literature

Alignment of Research Spend with Disease Severity & Incidence




* 3-yr overall survival reported

The Pathway to Therapies



Therapy Acceleration Program Model



TAP Goals
Therapies in clinical testing
Projects partnered for development
Drugs approved
Return on investment

Therapy Acceleration Program Pipeline

TARGET/THERAPY	INDICATION(S)	PRECLINICAL	PHASE I	PHASE II	PHASE III
PLK / PI3K <i>Estybon™</i>	MDS				
Apoptosis <i>CPX-351</i>	AML		 Phase II completed		
HDAC6 <i>ACY-1215</i>	Multiple Myeloma		 \$15 M Investment by 		
PI3K/HDAC	B-cell Lymphoma Myeloma				
Multi-IAP	Poor Risk AML		 Partnership with 		
BTK <i>AVL-292</i>	B-Cell Cancers		 Acquired by 		
HDAC <i>SHP-141</i>	CTCL				
DOT1L <i>Sm Molecule</i>	MLL Leukemia		 \$90 M Partnership with 		
VDA <i>OXI4503</i>	AML/MDS	 			
Resistance <i>CsA/TKI</i>	Leukemia	 			
Apoptosis <i>Ciclopirox</i>	Heme Malig	 	 Partnership with 		
CDC7 <i>MSK-777</i>	Acute Leukemias	 			
BCL6 <i>RI-BPI</i>	DLBCL				

The Learning Collaborative

Discovering and developing drugs for the treatment of rare hematological malignancies



**The
Learning
Collaborative™**



**LEUKEMIA &
LYMPHOMA
SOCIETY®**

fighting blood cancers

The Learning Collaborative

What was important?

- **Memorandum of Understanding sets collective objectives and manages expectations**
- **To enable commercialization: secure a Cooperative Research and Development Agreement**
- **Instill industry-quality project management in all activities**